Greg Gillum
Director, Medical Impact & Data Enablement Boehringer Ingelheim
Greg Gillum is Director of Medical Impact & Data Enablement at Boehringer Ingelheim, bringing over 20 years of experience across specialty sales and field-based medical affairs. A recognized subject matter expert in AI in Medical Affairs, Greg leads high-profile projects leveraging analytics and artificial intelligence to transform ways of working. His expertise spans medical affairs, field-based medicine, MSL engagement, oncology, and virology, with a focus on driving data-driven insights that enhance scientific impact and improve patient outcomes.
Seminars
As Medical Affairs becomes increasingly strategic and insight-driven, the challenge is shifting from collecting data to demonstrating meaningful impact. Each subfunction, from Field Medical to Communications, Evidence Generation and more adds unique value, but success depends on defining KPIs that capture both functional and collective achievement.
This practical workshop will help you build and align metrics that link everyday activities to broader organizational goals, using real-world examples to show how Medical Affairs drives measurable value for patients and the business
This workshop will gather experts to discuss:
- Define Fit-for-Purpose Metrics: Identify impactful KPIs for Field Medical, Medical Communications, and Evidence Generation teams
- Align Across Functions: Learn how to link function-specific metrics to overarching Medical Affairs strategy and corporate objectives
- Create Actionable Dashboards: Explore how to visualize and communicate KPI data to leadership and cross-functional partners
- Latest advancements in creating centralized insight portals, allowing HCPs and internal teams to access up-to-date clinical information
- Expanding Reach Beyond Professionals, looking to incorporate patient-generated data and insights into digital platforms to inform care strategies
- Understand how to tease apart the different contributions by the field, digital and other teams to quantify their impact on overall clinical and commercial outcomes
